HRS-4642

Unknown / undisclosed

Phase 3underway

Evidence outlook · registrational

Pancreatic Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-04.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Pancreatic Cancer
NCT07900789 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-10 – 2030-12-30 · Systemic Treatment-naïve Pancreatic Cancer
What this study did
NCT07232875 · Jiangsu HengRui Medicine Co., Ltd.
2025-11-21 – 2029-04 · KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
What this study did
Phase 2 (10)
Pancreatic Cancer
NCT06938282 · Shanghai Zhongshan Hospital
2025-06-23 – 2029-04-30 · Pancreatic Cancer
What this study did
NCT07691593 · Changhai Hospital
2026-06 – 2028-10 · Pancreatic Cancer
What this study did
NCT06770452 · Zhejiang University
2025-03-25 – 2028-02-01 · Metastatic Pancreatic Carcinoma
What this study did
NCT06587061 · Ruijin Hospital
2024-12-03 – 2027-12 · Pancreatic Cancer
What this study did
NCT07438106 · The First Affiliated Hospital with Nanjing Medical University
2026-01-28 – 2027-12 · Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
What this study did
NCT07131514 · Ruijin Hospital
2025-08-25 – 2027-12 · Pancreatic Cancer
What this study did
NCT06547736 · Fudan University
2024-10-14 – 2027-06 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT07503639 · Fudan University
2026-04 – 2030-04 · Locally Advanced Colorectal Cancer
What this study did
NCT07240766 · Zhejiang University
2026-02-15 – 2028-11-15 · Borderline Resectable Pancreatic Adenocarcinoma
What this study did
NCT06620848 · Shanghai Zhongshan Hospital
2024-11-21 – 2027-06-30 · Biliary Tract Cancer
What this study did
Phase 1/2 (7)
Pancreatic Cancer
NCT07806058 · Jiangsu HengRui Medicine Co., Ltd.
2026-10-15 – 2029-12-31 · Pancreatic Cancer
What this study did
NCT06427239 · Fudan University
2024-06-17 – 2028-03 · Pancreatic Cancer
What this study did
NCT07296341 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-01-08 – 2027-12 · Locally Advanced or Metastatic Pancreatic Cancer With
What this study did
Other / comorbidity
NCT06520488 · Jiangsu HengRui Medicine Co., Ltd.
2024-08-09 – 2027-07 · Advanced Solid Tumors
What this study did
NCT06773130 · West China Hospital
2025-02-10 – 2027-03 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT06955390 · Henan Cancer Hospital
2025-05-01 – 2026-12-01 · Solid Tumors
What this study did
NCT06385678 · Jiangsu HengRui Medicine Co., Ltd.
2024-07-05 – 2026-08 · Advanced KRAS G12D Mutant Solid Tumors
What this study did
Phase 1 (3)
Pancreatic Cancer
NCT07906691 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-11 – 2027-05 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT07894679 · The Third Xiangya Hospital of Central South University
2026-10 – 2026-11 · Drug Interactions
What this study did
NCT05533463 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-21 – 2025-12-30 · Advanced KRAS G12D Mutant Solid Tumors
What this study did

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Pancreatic Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-4642: this drugPhase 3UndisclosedKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
AtebimetinibPhase 3Small moleculeMEK (MAP2K1/2)not yet gradedNo reviewed efficacy summary in this indication
GFH375
Phase 3(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
INCB161734
Phase 3(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
Setidegrasib
Phase 3(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
TertomotidePhase 3PeptideTelomerase (hTERT)not yet gradedNo reviewed efficacy summary in this indication
ZoldonrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
CertepetidePhase 2PeptideAlpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway)not yet gradedNo reviewed efficacy summary in this indication
MotixafortidePhase 2PeptideCXCR4not yet gradedNo reviewed efficacy summary in this indication
Nogapendekin Alfa Inbakicept (Anktiva)Phase 2Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
INV-8989
Phase 1/2(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
QLC1101
Phase 1/2(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
TSN1611
Phase 1/2(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
Debecarasib
Phase 1(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LT-010391
Phase 1(overall)
Small moleculeKRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication
RG6620
—(overall)
UndisclosedKRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS-4642 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 1Drug InteractionsNot yet recruiting
Est. primary completion 2026-11 · NCT07894679 · CT.gov ↗
What to watch
December 2026 (1)
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2026-12-31 · NCT06620848 · CT.gov ↗
What to watch
2027 (12)
February 2027 (2)
Phase 1Pancreatic CancerNot yet recruiting
Est. primary completion 2027-02 · NCT07906691 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-02-01 · NCT06770452 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-03 · NCT06520488 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-04-30 · NCT06938282 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Borderline Resectable Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT07240766 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT06427239 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT06587061 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT07131514 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-10 · NCT07296341 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-10 · NCT07438106 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07691593 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 2Locally Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07503639 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2028-12-31 · NCT07806058 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2029-04 · NCT07232875 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 3Pancreatic CancerNot yet recruiting
Est. primary completion 2030-11-30 · NCT07900789 · CT.gov ↗
What to watch

See the full readout calendar ↗